Key Points
- To evaluate the pharmacological properties, receptor selectivity, and organ-protective capabilities of the non-peptide endothelin A receptor antagonist LU 135252 across experimental cardiovascular and renal disorders.
- Synthesized findings from preclinical in vitro, in vivo animal models, and early human tolerability and pharmacokinetic studies investigating orally administered LU 135252.
- Assessed hemodynamic, vascular remodeling, and tissue injury endpoints in models of hypertension, congestive heart failure, myocardial ischemia-reperfusion, and acute or chronic renal disease.
- LU 135252 exhibited potent and highly selective antagonism at endothelin A receptors, effectively blocking endothelin-1-induced vasoconstriction and cellular proliferation.
- Experimental treatment significantly reduced blood pressure in salt- and angiotensin II-dependent hypertension while preventing left ventricular remodeling and cardiac hypertrophy in heart failure models.
- Administration preserved microvascular perfusion, attenuated myocardial ischemia-reperfusion damage, reduced neointima formation after vascular injury, and ameliorated postischemic acute renal failure.
Structured PICO
IInterventionLU 135252 (EndothelinA Receptor Antagonist)
This paper provides a review of the pharmacology of the endothelin A receptor antagonist LU 135252.